Pharmaceutical

STAT+: U.K., pharma industry strike deal for how the NH...

The U.K. and pharma industry have reached a deal on how the health system pays f...

STAT+: What Eli Lilly’s Zepbound reveals about the intr...

The story behind the Zepbound moniker offers insight into the marketing differen...

STAT+: How a major hospital shows just how inflated hos...

Hospitals’ list prices always come with massive discounts. Financial documents a...

STAT+: Hospitals put tech spending on a tight leash, ra...

Hospital leaders have become increasingly cautious about their spending and the ...

Respiratory viruses, thrown out of whack by Covid, appe...

As we head into the fourth Northern Hemisphere winter of the Age of Covid, respi...

Takeda wins EU approval for paediatric use of Takhzyro ...

The European Commission has approved the label expansion of Takeda’s Takhzyro (...

Oxurion to file for bankruptcy following trial failure

Oxurion has started to file for bankruptcy after the Phase IIb trial investigat...

Pfizer licenses small molecule drug delivery technology...

Pfizer has entered a licence agreement with Serina Therapeutics for its drug de...

Monash University team to receive funds for prostate ca...

A team of researchers at Monash University in Australia will receive a $5m ...

AstraZeneca launches new digital health solutions busin...

AstraZeneca has launched Evenova, a new digital health solutions business, with...

Bayer announces recall of cancer therapy Vitrakvi in US

Bayer has announced a voluntary recall of a single lot of its cancer therapy Vi...

EC approves BeiGene’s Brukinsa combo to treat follicula...

The European Commission (EC) has granted marketing authorisation to BeiGene’s B...

NeoImmuneTech bags orphan drug tag for IL-7 acute radia...

The US Food and Drug Administration (FDA) awarded an orphan drug designation to...

Chiesi partners with Haisco to commercialise bronchiect...

Chiesi Group and Haisco Pharmaceutical have entered a licence agreement to join...

Signal: Wegovy highlights UK’s complex relationship wit...

A number of stories in the UK have emerged around Novo Nordisk’s blockbuster we...

STAT+: Key questions (and answers) about the historic a...

Here are some key questions (and answers) about the historic approval of a CRISP...